GlaxoSmithKline diabetes drug faces U.S. approval delay
LONDON (Reuters) - U.S. regulators have pushed back an approval decision on GlaxoSmithKline's experimental diabetes drug albiglutide by three months until April 15, 2014, Britain's biggest drugmaker said on Friday.
A separate filing for the drug in Europe is progressing on schedule.
The once-weekly treatment for type 2 diabetes belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca.
Based on reported clinical trial results, industry analysts have questioned how well albiglutide will fare in a crowded market - especially with a promising new rival in the pipeline in the form of Eli Lilly's dulaglutide.
(Reporting by Ben Hirschler; Editing by Keith Weir)
- Target stores' customers hit by major credit card attack
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Facebook, Zuckerberg, banks must face IPO lawsuit: judge
- As Modi storms into India's election, a quiet alternative emerges
- U.S. prosecutor defends treatment of Indian diplomat |
During Soviet times, Sochi gained a reputation for tolerance but the city's once vibrant gay scene has been shrinking as Russia prepares to host the 2014 Winter Games. Slideshow